HHU Stock Chart & Stats
€0.06
<€0.01(10.91%)
At close: 4:00 PM EDT
€0.06
<€0.01(10.91%)
Day’s Range― - ―
52-Week Range€0.05 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)14.35K
Market Cap
€442.46M
Enterprise Value€591.39
Total Cash (Recent Filing)€10.08M
Total Debt (Recent Filing)€26.75M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Sep 24, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding6,332,530,000
10 Day Avg. Volume8,961
30 Day Avg. Volume14,350
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)-13.44
Price to Sales (P/S)6.88
P/FCF Ratio-11.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€3.00M
Bulls Say, Bears Say
Bulls Say
Specialized AIT Business ModelA focused specialty model in allergen immunotherapy creates durable competitive advantage: deep clinical expertise, regulatory know-how and therapy-specific manufacturing act as barriers to entry, supporting repeat prescribing and long-term customer relationships with healthcare providers.
Established European Regulated FootprintA presence across regulated European markets supports stable reimbursement pathways and regulatory experience. That geographic focus reduces market-entry uncertainty, enables scale in core markets, and strengthens distributor and payer relationships over multiple regulatory cycles.
Broad AIT And Diagnostics PortfolioCombining allergy vaccines with complementary diagnostics creates cross-sell opportunities and improves patient targeting. Integrated product sets increase clinical stickiness and can raise lifetime revenue per patient, supporting steadier commercial revenue streams over time.
Bears Say
Negative Shareholders' EquityNegative equity and elevated leverage materially weaken the balance sheet, limiting capacity to absorb shocks and increasing refinancing and covenant risk. This structural fragility reduces strategic optionality and raises the likelihood of dilutive or costly financing over months.
Persistent Negative Cash FlowSustained negative operating and free cash flow undermines self-funding for R&D and commercial expansion. Large FCF deterioration forces reliance on external capital, elevating solvency risk and potentially constraining investment in manufacturing or new product development.
Declining Revenue And Heavy LossesA structural decline in revenue combined with large net losses and negative margins indicates weak demand or margin pressure. Over months, this impedes scale economics, reduces reinvestment capacity, and makes reaching sustained profitability more challenging without strategic change.
Allergy Therapeutics News
HHU FAQ
What was Allergy Therapeutics PLC’s price range in the past 12 months?
Allergy Therapeutics PLC lowest stock price was €0.05 and its highest was €0.16 in the past 12 months.
What is Allergy Therapeutics PLC’s market cap?
Allergy Therapeutics PLC’s market cap is €442.46M.
When is Allergy Therapeutics PLC’s upcoming earnings report date?
Allergy Therapeutics PLC’s upcoming earnings report date is Sep 24, 2026 which is in 50 days.
How were Allergy Therapeutics PLC’s earnings last quarter?
Allergy Therapeutics PLC released its earnings results on Mar 31, 2026. The company reported -€0.005 earnings per share for the quarter, the consensus estimate of -€0.005 by €0.
Is Allergy Therapeutics PLC overvalued?
According to Wall Street analysts Allergy Therapeutics PLC’s price is currently Overvalued.
Does Allergy Therapeutics PLC pay dividends?
Allergy Therapeutics PLC does not currently pay dividends.
What is Allergy Therapeutics PLC’s EPS estimate?
Allergy Therapeutics PLC’s EPS estimate is >-0.01.
How many shares outstanding does Allergy Therapeutics PLC have?
Allergy Therapeutics PLC has 6,332,530,000 shares outstanding.
What happened to Allergy Therapeutics PLC’s price movement after its last earnings report?
Allergy Therapeutics PLC reported an EPS of -€0.005 in its last earnings report, expectations of -€0.005. Following the earnings report the stock price went down -2.679%.
Which hedge fund is a major shareholder of Allergy Therapeutics PLC?
Currently, no hedge funds are holding shares in DE:HHU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Allergy Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
85.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.69%
Trailing 12-Months
Company Description
Allergy Therapeutics PLC
Allergy Therapeutics plc is a biotechnology firm dedicated to the research and development of innovative treatments for allergies. The company offers a range of injectable and sublingual immunotherapies specifically targeting allergens, alongside diagnostic tools and prescription solutions for pollen-related allergies, including those caused by grasses, weeds, and trees. Its diverse product portfolio features Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. Furthermore, Allergy Therapeutics is actively advancing new vaccine candidates designed to address sensitivities to trees, grass, house dust mites, animal dander, and peanuts. With operations spanning Central Europe, Southern Europe, the United Kingdom, and various other international markets, Allergy Therapeutics plc was established in 2004 and is headquartered in Worthing, UK.
Technical Analysis
Animalcare
―
Hikma Pharmaceuticals
―
Shield Therapeutics
―
Venture Life
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―